Literature DB >> 21083646

Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood.

G L Mendolicchio1, D Zavalloni, M Bacci, E Corrada, M Marconi, C Lodigiani, P Presbitero, L Rota, Z M Ruggeri.   

Abstract

BACKGROUND AND OBJECTIVES: Patients treated with percutaneous coronary intervention receive aspirin and P2Y12 ADP receptor inhibitors to reduce thrombotic complications. The choice of methodology for monitoring the effects of treatment and assessing its efficacy is still a topic of debate. We evaluated how decreased P2Y12 function influences platelet aggregate (thrombus) size measured ex vivo. METHODS AND
RESULTS: We used confocal videomicroscopy to measure in real time the volume of platelet thrombi forming upon blood perfusion over fibrillar collagen type I at a wall shear rate of 1500 s(-1). The average volume was significantly smaller in 31 patients receiving aspirin and clopidogrel (19) or ticlopidine (12) than in 21 controls, but individual values were above the lower limit of the normal distribution, albeit mostly within the lower quartile, in 61.3% of cases. Disaggregation of platelet thrombi at later perfusion times occurred frequently in the patients. Vasodilator-stimulated phosphoprotein phosphorylation, reflecting P2Y12 inhibition, was also decreased in the patient group, and only 22.6% of individual values were above the lower normal limit. We found no correlation between volume of thrombus formed on collagen fibrils and level of P2Y12 inhibition, suggesting that additional and individually variable factors can influence the inhibitory effect of treatment on platelet function.
CONCLUSIONS: Measurements of platelet thrombus formation in flowing blood reflects the consequences of antiplatelet therapy in a manner that is not proportional to P2Y12 inhibition. Combining the results of the two assays may improve the assessment of thrombotic risk.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21083646      PMCID: PMC3030676          DOI: 10.1111/j.1538-7836.2010.04144.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  46 in total

1.  Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

Authors:  Anna Maria Gori; Rossella Marcucci; Angela Migliorini; Renato Valenti; Guia Moschi; Rita Paniccia; Piergiovanni Buonamici; Gian Franco Gensini; Ruben Vergara; Rosanna Abbate; David Antoniucci
Journal:  J Am Coll Cardiol       Date:  2008-08-26       Impact factor: 24.094

2.  The challenge of monitoring platelet response after clopidogrel.

Authors:  Victor L Serebruany; Shinya Goto
Journal:  Eur Heart J       Date:  2008-10-30       Impact factor: 29.983

Review 3.  Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.

Authors:  Nina C Raju; John W Eikelboom; Jack Hirsh
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-10-28

4.  Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients.

Authors:  Marie Lordkipanidzé; Chantal Pharand; Thuy Anh Nguyen; Erick Schampaert; Donald A Palisaitis; Jean G Diodati
Journal:  Eur Heart J       Date:  2008-09-30       Impact factor: 29.983

5.  The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.

Authors:  Rüdiger Blindt; Katja Stellbrink; Anita de Taeye; Robert Müller; Paul Kiefer; Eray Yagmur; Christian Weber; Malte Kelm; Rainer Hoffmann
Journal:  Thromb Haemost       Date:  2007-12       Impact factor: 5.249

6.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321

7.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

8.  Genetic determinants of response to clopidogrel and cardiovascular events.

Authors:  Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

9.  Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function.

Authors:  Anna Maria Gori; Rossella Marcucci; Rita Paniccia; Betti Giusti; Sandra Fedi; Emilia Antonucci; Piergiovanni Buonamici; David Antoniucci; Gian Franco Gensini; Rosanna Abbate
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

10.  Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis.

Authors:  Olivier Morel; Antoine Faure; Patrick Ohlmann; Laurence Jesel; Dominique Desprez; Lelia Grunebaum; Pierre Bareiss
Journal:  Thromb Haemost       Date:  2007-10       Impact factor: 5.249

View more
  10 in total

Review 1.  The role of P2Y₁₂ receptor and activated platelets during inflammation.

Authors:  Elisabetta Liverani; Laurie E Kilpatrick; Alexander Y Tsygankov; Satya P Kunapuli
Journal:  Curr Drug Targets       Date:  2014       Impact factor: 3.465

2.  Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay.

Authors:  Ruizhi Li; Scott L Diamond
Journal:  Thromb Res       Date:  2013-11-06       Impact factor: 3.944

Review 3.  The Function and Regulation of Platelet P2Y12 Receptor.

Authors:  Xiaohua Li; Guoxing Zhang; Xia Cao
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-28       Impact factor: 3.727

4.  Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs.

Authors:  Gillian Stephens; Ming He; Connie Wong; Marzena Jurek; Hans-Christian Luedemann; Golnaz Shapurian; Kevin Munnelly; Craig Muir; Pamela B Conley; David R Phillips; Patrick Andre
Journal:  Thromb J       Date:  2012-08-01

5.  Platelet function tests: why they fail to guide personalized antithrombotic medication.

Authors:  Diana A Gorog; Young-Hoon Jeong
Journal:  J Am Heart Assoc       Date:  2015-05-26       Impact factor: 5.501

6.  Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses.

Authors:  Melissa Li; Nathan A Hotaling; David N Ku; Craig R Forest
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

7.  Identification of platelet function defects by multi-parameter assessment of thrombus formation.

Authors:  Susanne M de Witt; Frauke Swieringa; Rachel Cavill; Moniek M E Lamers; Roger van Kruchten; Tom Mastenbroek; Constance Baaten; Susan Coort; Nicholas Pugh; Ansgar Schulz; Inge Scharrer; Kerstin Jurk; Barbara Zieger; Kenneth J Clemetson; Richard W Farndale; Johan W M Heemskerk; Judith M E M Cosemans
Journal:  Nat Commun       Date:  2014-07-16       Impact factor: 14.919

8.  Differential integrin activity mediated by platelet collagen receptor engagement under flow conditions.

Authors:  Nicholas Pugh; Ben D Maddox; Dominique Bihan; Kirk A Taylor; Martyn P Mahaut-Smith; Richard W Farndale
Journal:  Thromb Haemost       Date:  2017-05-24       Impact factor: 5.249

9.  Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays.

Authors:  Keith B Neeves; Abimbola A Onasoga; Ryan R Hansen; Jessica J Lilly; Diana Venckunaite; Meghan B Sumner; Andrew T Irish; Gary Brodsky; Marilyn J Manco-Johnson; Jorge A Di Paola
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

10.  SDF-1α is a novel autocrine activator of platelets operating through its receptor CXCR4.

Authors:  Tony G Walsh; Matthew T Harper; Alastair W Poole
Journal:  Cell Signal       Date:  2014-10-05       Impact factor: 4.315

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.